If there’s one thing giving Mylan analysts pause, it’s the company’s plans to ramp up 2019 spending. It's true that the company is in the midst of rolling out several key drugs—but whether that extra outlay can pay off is the question.
Published: Feb 27 2019
Would you like to be included in the directory? Let us know!